1225713-29-0

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-(methylsulfonamido)benzoic acid is used as a key reactant for the synthesis of pyrazolo[1,5-a]pyrimidines, which are known for their antiviral properties. These compounds have the potential to inhibit viral replication and are being explored as therapeutic agents against various viral infections.
In the development of antiviral agents, 5-bromo-2-(methylsulfonamido)benzoic acid plays a crucial role as a starting material or intermediate in the chemical synthesis process. Its unique functional groups allow for further modification and optimization of the resulting pyrazolo[1,5-a]pyrimidines to enhance their antiviral activity and selectivity.
Additionally, the compound may find applications in other areas of drug discovery, such as the development of novel anticancer, anti-inflammatory, or analgesic agents, due to its diverse chemical reactivity and potential for structural modification. However, further research and development are necessary to fully explore and understand the scope of its applications in these areas.

Upstream product

• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 452350-33-3 methyl 5-bromo-2-[(methylsulfonyl)amino]benzoate 

Downstream Products

• 1353629-38-5 C₂₀H₂₁BrClN₅O₃S 
• 1353623-64-9 C₂₆H₃₂BrN₇O₅S 
• 1353623-63-8 C₂₆H₃₂BrN₇O₄S 
• 1353628-72-4 C₂₃H₂₆BrClN₆O₄S 
• 1353623-66-1 C₂₃H₂₇BrN₆O₄S 

Relevant academic research and scientific papers

NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS

The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endopara

Pyrazolo[1,5-A]pyrimidines as antiviral agents

The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study

GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit. The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochemical properties were optimized by introducing the para-chloro and aminopyrrolidine groups. A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clinical isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection. Oral bioavailability in preclinical species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue. In healthy human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a mean 4.2 log10 reduction in peak viral load and a significant reduction in disease severity compared to placebo. In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.

New compounds

The present invention relates to a new compound of formula wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasite

PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS

The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.